SureTrader
Nadex Advertisement
Interactive Brokers Advertisement
Home > Boards > US OTC > Medical - Drugs >

Innovation Pharmaceuticals Inc. (IPIX)

IPIX RSS Feed
Add IPIX Price Alert      Hide Sticky   Hide Intro
Moderator: LilBigKahuna, BooDog, sox040713, Astavakra, TheHound, Matagordaville
Search This Board: 
Last Post: 7/22/2017 6:39:04 PM - Followers: 720 - Board type: Free - Posts Today: 75

Innovation Pharmaceuticals Inc. (IPIX)

https://www.sec.gov/Archives/edgar/data/1355250/000147793217002710/ctix_8k.htm
 

http://www.ipharminc.com/

 
Company Address:
100 Cumming Center, Suite 151-B
Beverly, MA 01915
Phone: 978-236-8717
Fax:  978-921-6564
Email:  info@ipharminc.com

 
About Innovation Pharmaceuticals Inc.: 

Headquartered in Beverly, Massachusetts, Innovation Pharmaceuticals is a publicly-traded company under the symbol "IPIX".
Innovation Pharmaceuticals is a clinical stage biopharmaceutical company developing innovative therapies in multiple diseases. Innovation Pharmaceuticals believes it has a world-class portfolio of first-in-class lead drug candidates and is now advancing them toward market approval, while actively seeking strategic partnerships. Innovation Pharmaceuticals' psoriasis drug candidate Prurisol completed a Phase 2 trial and Innovation Pharmaceuticals is nearing completion of a Phase 2b study. Prurisol is a small molecule that acts through immune modulation and PRINS reduction. Innovation Pharmaceuticals' anti-cancer drug Kevetrin successfully concluded a Phase 1 clinical trial at Harvard Cancer Centers' Dana Farber Cancer Institute and Beth Israel Deaconess Medical Center, and Innovation Pharmaceuticals has commenced a Phase 2 study. In the laboratory, Kevetrin has shown to induce activation of p53, often referred to as the "Guardian Angel Gene" due to its crucial role in controlling cell mutations. Innovation Pharmaceuticals is in a Phase 2 clinical trial with its novel compound Brilacidin-OM (a defensin mimetic compound) for the prevention of oral mucositis in patients with head and neck cancer. Interim analysis has shown Brilacidin-OM to have a high potential for prevention of severe oral mucositis. Clinical results are consistent with those seen in an animal model in which the occurrence of severe ulcerative oral mucositis was reduced by more than 94% compared to placebo. Innovation Pharmaceuticals' lead antibiotic, Brilacidin, has completed a Phase 2b trial for Acute Bacterial Skin and Skin Structure Infection, or ABSSSI. Top-line data have shown a single dose of Brilacidin to deliver comparable clinical outcomes to the FDA-approved seven-day dosing regimen of daptomycin. Brilacidin has the potential to be a single-dose therapy for certain multi-drug resistant bacteria ("superbugs"). In an ongoing Phase 2 open label Proof-of-Concept trial, favorable interim results have been observed in the first two cohorts of patients treated with Brilacidin for Ulcerative Proctitis/Ulcerative Proctosigmoiditis (UP/UPS), two types of Inflammatory Bowel Disease (IBD).  Innovation Pharmaceuticals has formed research collaborations with world-renowned research institutions in the United States and Europe, including MD Anderson Cancer Center, Beth Israel Deaconess Medical Center, and the University of Bologna. More information is available at http://www.ipharminc.com.

Management: http://www.cellceutix.com/senior-management/

Ongoing Human Trials:  http://clinicaltrials.gov/ct2/results?term=Cellceutix+Pharmaceuticals&Search=Search
 
Product Pipeline:  http://www.ipharminc.com/therapeutic-areas/

 

PIPELINE: 

FDA DESIGNATIONS:

 

COMPLETED/UPCOMING MILESTONES:


Recent News and Press Releases: 
https://finance.yahoo.com/quote/IPIX?p=IPIX
http://www.ipharminc.com/press-release/

 
SEC Filings (CIK:0001355250): 
https://www.sec.gov/cgi-bin/browse-edgar?company=Innovation+Pharmaceutical&owner=exclude&action=getcompany

Transfer Agent:
West Coast Stock Transfer, Inc.
721 N. Vulcan Ave. Ste. 205
Encinitas, CA 92024
(619) 664-4780 p
(760) 452-4423 f
cs@wcsti.com
http://www.westcoaststocktransfer.com

 
Share Structure:  See SEC filing link above for current share structure

 

Cellceutix IP - Patent Filings:

EPO
http://worldwide.espacenet.com/searchResults?PA=Cellceutix&DB=EPODOC&locale=en_EP&ST=advanced&compact=false
WIPO
http://www.wipo.int/patentscope/search/en/detail.jsf?docId=WO2010135170&recNum=1&docAn=US2010034838&queryString=FP:(Cellceutix)&maxRec=1
USPTO
http://appft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&r=0&f=S&l=50&TERM1=Cellceutix&FIELD1=AS&co1=AND&TERM2=&FIELD2=&d=PG01 


http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=8,796,275.PN.&OS=PN/8,796,275&RS=PN/8,796,275
 

Publication number US8338454 B2
Publication type Grant
Application number US 12/780,132
Publication date Dec 25, 2012
Filing date May 14, 2010
Priority date May 20, 2009
Also published as CA2762427A1, CN102438612A, EP2432464A2, US20100298374, US20130245062, WO2010135170A2, WO2010135170A3, Less «6 More »
Publication number 12780132, 780132, US 8338454 B2, US 8338454B2, US-B2-8338454, US8338454 B2, US8338454B2
Inventors Krishna Menon
Original Assignee Cellceutix Corporation
Export Citation BiBTeX, EndNote, RefMan
Patent Citations (6), Non-Patent Citations (41), Referenced by (1), Classifications (42)
 
External Links: USPTO, USPTO Assignment, Espacenet

http://www.google.com/patents/US8338454

http://appft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&r=6&f=G&l=50&co1=AND&d=PG01&s1=Cellceutix.AS.&OS=AN/Cellceutix&RS=AN/Cellceutix

 
Investor Relations: 

http://www.ipharminc.com/new-faq/
http://www.ipharminc.com/contact-us-1


Following is a DAILY chart:


 

All messages, including iBox content, are the opinion of the posters, are no substitute for your own research, and should not be relied upon for stock trading or any other purpose.
 
Also, keep in mind that moderators may or may not have a position in said stock.  Being a moderator isn’t a sign of endorsement.
 
Please keep your posts on topic because your message(s) will probably be deleted when:
* Posting content that's off-topic to the subject of this board;
* Posting statements that don't add value to the discussion; or
* When you violate any other posting term of the iHub User Agreement: http://investorshub.advfn.com/boards/complex_terms.asp

IPIX
Current Price
Volume:
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
IPIX News: Current Report Filing (8-k) 07/13/2017 04:04:10 PM
IPIX News: Current Report Filing (8-k) 06/07/2017 04:19:05 PM
IPIX News: Quarterly Report (10-q) 05/09/2017 04:09:09 PM
IPIX News: Amended Statement of Ownership (sc 13g/a) 04/28/2017 12:50:45 PM
IPIX News: Bahamas Development Corp. (OTC Pink: BDCI) $2.4 Million in Sales and 10% Quarterly Growth – Issues Guidance 04/17/2017 07:03:27 AM
PostSubject
#191274  Sticky Note >80% of Prurisol patients should finish six weeks sox040713 07/21/17 11:47:02 AM
#190524  Sticky Note IPIX Milestones, Clinical Trials, Recent Interviews, Fact Sheets, Blogs sox040713 07/16/17 03:13:55 PM
#190087  Sticky Note From the June conference call, sox040713 07/13/17 06:15:25 PM
#187089  Sticky Note Prurisol's Importance: data We are nearing the very DaubersUP 06/23/17 04:59:13 PM
#187085  Sticky Note When it is easier to find an off IH Admin [Edward] 06/23/17 04:39:38 PM
#191401   my question is this...we know that tampa is untohim 07/22/17 06:39:04 PM
#191400   It has to be P, why would Seth Rdunn88 07/22/17 06:37:58 PM
#191399   Psoriasis is the most prevalent autoimmune disease in georgejjl 07/22/17 06:34:03 PM
#191398   Dr Forman is likely assisting in multiple psoriasis KarinCA 07/22/17 06:30:02 PM
#191397   Hard to say definitively..time will tell...patience is needed... Golfguru03 07/22/17 06:28:22 PM
#191396   I'm more convinced now after reading Seth Foreman's Rdunn88 07/22/17 06:25:25 PM
#191395   The important point is that another oral treatment KarinCA 07/22/17 06:19:36 PM
#191394   Good catch, Seth Foreman lists Cellceutix in his Rdunn88 07/22/17 06:16:02 PM
#191393   Clear in my mind the drug being referred Relentless4ever 07/22/17 06:11:46 PM
#191392   Also, there can be other trials on-going and Rdunn88 07/22/17 06:08:11 PM
#191391   Seth Forman Clinical research consultant for protocol development, untohim 07/22/17 06:06:15 PM
#191390   we can't correlate this flyer with this news untohim 07/22/17 05:58:56 PM
#191389   It's looking more and more like the article thefamilyman 07/22/17 05:57:57 PM
#191388   excuse me dont they have a trial for untohim 07/22/17 05:54:17 PM
#191387   ok he mentions this in a comment but untohim 07/22/17 05:47:47 PM
#191386   In the Flyer... One thing of note, they Rdunn88 07/22/17 05:43:48 PM
#191385   also the 26 weeks vs our 16 weeks untohim 07/22/17 05:40:52 PM
#191384   Where doesit say anywhere about a 26 week study?????? untohim 07/22/17 05:39:26 PM
#191383   Must read! Prurisol trial is recruiting in Tampa, untohim 07/22/17 05:33:08 PM
#191382   Actually, good news for P... A 26 week Rdunn88 07/22/17 05:31:04 PM
#191381   If you pause and look at the small georgejjl 07/22/17 05:30:12 PM
#191380   It might be that Forward Clinical Trials made thefamilyman 07/22/17 05:27:57 PM
#191379   Amen JUST 10-11-12 07/22/17 05:22:32 PM
#191378   IPIX HEADQUARTERS : » ....Knock,Knock....Who's There ???...Big Bio-pharma...can tryz 07/22/17 05:20:30 PM
#191377   Could still be chasing Monday morning because P septmike09 07/22/17 04:59:25 PM
#191376   Good thing you guys were on top of alwaysdreaming 07/22/17 04:56:53 PM
#191375   Yep, if P interim/final are a success the Rdunn88 07/22/17 04:56:17 PM
#191374   Is good to see a story about Oral slcimmuno 07/22/17 04:27:49 PM
#191373   The key to what the trial doctor mentioned Rdunn88 07/22/17 04:19:31 PM
#191372   That's what I would be thinking. "Get cured and thefamilyman 07/22/17 04:19:00 PM
#191371   We're all hoping for price increase way beyond Blue Fin 07/22/17 04:18:54 PM
#191370   Unless they have already unblinded and know what's F1ash 07/22/17 04:18:38 PM
#191369   Ah good catch F1...my bad. Shouldn't have FlashingLeather 07/22/17 04:17:22 PM
#191368   There's little doubt in my mind we're going Relentless4ever 07/22/17 04:15:44 PM
#191367   Here's their flyer on that Psoriasis study. https://realtime-host01.com/fct/fl thefamilyman 07/22/17 04:14:41 PM
#191366   Abbvie has Humira, but that's been approved with Rdunn88 07/22/17 04:10:55 PM
#191365   "Group B (n=81): Placebo" https://clinicaltrials.gov/ct2/show/NCT029493 F1ash 07/22/17 04:07:18 PM
#191364   I agree, Also, there may be an agreement Rdunn88 07/22/17 03:59:44 PM
#191363   Ehrlich Rd? LMAO. septmike09 07/22/17 03:59:36 PM
#191362   Here's the flyer for the trial: FlashingLeather 07/22/17 03:57:11 PM
#191361   Yep just another sign that P is kicking butt. septmike09 07/22/17 03:56:26 PM
#191360   I did a freeze frame on the pill Cassius Longinus 07/22/17 03:53:28 PM
#191359   yup. Tampa FL and 33 other locations across TheHound 07/22/17 03:49:34 PM
#191358   Agree, this has to be the Prurisol trial Relentless4ever 07/22/17 03:46:54 PM
#191357   Yes, Tampa has a clinical study site for Prurisol... Rdunn88 07/22/17 03:43:23 PM
#191356   Is Tampa where IPIX is testing now? tia jsc52033 07/22/17 03:34:34 PM
#191355   Mike, I doubt there's another pill-form Psoriasis trial Rdunn88 07/22/17 03:33:41 PM
#191354   If they are indeed talking about Prurisol, this septmike09 07/22/17 03:18:33 PM
#191353   Whoever posted that was incorrect. The kevetrin KarinCA 07/22/17 03:10:31 PM
#191352   Tampa news story about IPIX trial... The need Rdunn88 07/22/17 02:46:12 PM
PostSubject